Envoy Medical (COCH) Common Equity (2021 - 2026)

Envoy Medical (COCH) has 6 years of Common Equity data on file, last reported at $10.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 141.95% year-over-year to $10.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.2 million (up 141.95% YoY), and the FY2025 full-year result was -$12.2 million, up 35.47% from the prior year.
• Common Equity grew to $10.2 million in Q1 2026, from -$12.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $10.2 million in Q1 2026 to a low of -$47.5 million in Q1 2023.
• A 5-year average of -$19.1 million and a median of -$18.8 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 960.92% in 2024 and surged 141.95% in 2026, its largest moves.
• Tracing COCH's Common Equity over 5 years: stood at -$36.2 million in 2022, then soared by 95.09% to -$1.8 million in 2023, then sank by 960.92% to -$18.8 million in 2024, then jumped by 35.47% to -$12.2 million in 2025, then jumped by 183.57% to $10.2 million in 2026.
• Business Quant data shows COCH's Common Equity at $10.2 million in Q1 2026, -$12.2 million in Q4 2025, and -$7.7 million in Q3 2025.